Interne link ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets december 08, 2023 om 12:30 PM UTC
Interne link ProQR Announces Third Quarter 2023 Operating and Financial Results november 07, 2023 om 12:00 PM UTC
Interne link ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing november 06, 2023 om 12:00 PM UTC
Interne link ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference september 28, 2023 om 12:00 PM UTC
Interne link ProQR Therapeutics Provides Update on Ophthalmic Assets september 27, 2023 om 11:00 AM UTC
Interne link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference september 07, 2023 om 12:00 PM UTC
Interne link ProQR Announces Second Quarter 2023 Operating and Financial Results augustus 03, 2023 om 11:00 AM UTC
Interne link ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets augustus 01, 2023 om 11:00 AM UTC
Interne link ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit juli 06, 2023 om 11:00 AM UTC
Interne link ProQR Announces First Quarter 2023 Operating and Financial Results mei 16, 2023 om 11:00 AM UTC
Interne link ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 mei 09, 2023 om 12:00 PM UTC
Interne link ProQR Announces Upcoming Investor Conferences in April and May april 20, 2023 om 12:00 PM UTC
Interne link ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023 april 18, 2023 om 12:00 PM UTC
Interne link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event maart 29, 2023 om 12:00 PM UTC
Interne link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing maart 14, 2023 om 12:00 PM UTC
Interne link ProQR to Present at Upcoming Scientific and Industry Conferences maart 07, 2023 om 01:00 PM UTC
Interne link ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023 februari 28, 2023 om 01:00 PM UTC
Interne link ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa december 11, 2019 om 12:00 PM UTC
Interne link ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa november 21, 2019 om 12:00 PM UTC
Interne link ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019 november 06, 2019 om 12:00 PM UTC
Interne link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares oktober 18, 2019 om 12:20 PM UTC
Interne link ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares oktober 16, 2019 om 03:17 AM UTC
Interne link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares oktober 15, 2019 om 09:15 PM UTC